Welcome to our dedicated page for WORK Medical Technology Group news (Ticker: WOK), a resource for investors and traders seeking the latest updates and insights on WORK Medical Technology Group stock.
WORK Medical Technology Group LTD (Nasdaq: WOK) is a medical devices company that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through subsidiaries in China. Its news flow, as reflected in company press releases and SEC reports, spans product development, regulatory milestones, capital markets activity, and strategic collaborations.
Readers following WOK news can track updates on WORK Medical’s portfolio of medical consumables, including customized and multifunctional masks and other disposable devices, as well as its expansion into AI-enabled diagnostic equipment. A key recent theme is the company’s AI-Automated Human Blood Cell Morphology Analyzer, a Class II medical device developed by subsidiary Hunan Saitumofei. News items cover manufacturing approval from a Chinese regulatory authority, technical capabilities of the analyzer, and an exclusive distribution agreement with Shanghai Benke Medical Technology Co., Ltd. for East China.
WORK Medical’s news also includes announcements on equity investments and partnerships. The company has reported a 10% equity investment in Neologics Bioscience Inc., a Delaware-based medical technology firm focused on integrating artificial intelligence and medicine, and subsequent service agreements between Neologics and GemPharmatech Corporation. In addition, WORK Medical has disclosed a strategic cooperation agreement with Hong Kong Web3.0 Standardization Association Limited to explore blockchain and Real-world Asset technology applications.
Capital markets and listing-related developments form another important category of WOK news. The company has issued press releases on registered direct offerings, at-the-market offering arrangements, reverse stock splits, and communications from Nasdaq regarding minimum bid price compliance and potential delisting determinations. For investors and observers, the WOK news page on Stock Titan provides a centralized view of these disclosures, helping users review product, regulatory, financing, and governance announcements in one place.
WORK Medical (Nasdaq: WOK) subsidiary Hunan Saitumofei granted Shanghai Benke exclusive distribution rights for the AI-Automated Blood Cell Morphology Analyzer (CM-B600) in East China (Jiangsu, Shanghai, Zhejiang) from Jan 1 to Dec 31, 2026.
The Agreement sets a minimum annual sales target of RMB 10 million and includes a RMB 1 million prepaid performance bond. The Analyzer received Class II manufacturing approval in Nov 2025, supports up to 150 samples per batch, average detection time ≤ 3 minutes per smear, classification accuracy ≥ 90% for major WBC types, identification of 17 WBC subtypes, and a database > 350,000 images.
WORK Medical Technology Group (Nasdaq: WOK) announced that its subsidiary Hunan Saitumofei received manufacturing approval from the Hunan Provincial Medical Products Administration for a Class II AI‑Automated Human Blood Cell Morphology Analyzer on December 29, 2025. The analyzer combines a main optical imaging unit and embedded analysis software to perform white blood cell differentials and quantify red blood cell and platelet morphology using deep‑learning algorithms.
Manufacturing is scheduled to begin in the first half of 2026. The company says the device aims to increase efficiency, consistency, and accuracy in microscopic exams, reduce manual workload and costs, and support early screening and quality control in hematology and oncology settings.
WORK Medical (Nasdaq: WOK) announced a 1-for-100 reverse stock split of its Class A and Class B ordinary shares, effective when markets open on December 29, 2025. The action was approved by the board and shareholders and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2) on minimum bid price. Shares will continue to trade on the Nasdaq Capital Market under the symbol WOK with a new CUSIP G9767H125. Fractional shares will be rounded up to the next whole share; no fractional shares will be issued. The reverse split combines every 100 issued and outstanding Class A or Class B shares into one share, and does not change percentage ownership except for rounding adjustments.
WORK Medical (Nasdaq: WOK) announced that its subsidiary Neologics Bioscience entered a service agreement with GemPharmatech on Nov 4, 2025 to provide antibody R&D testing and in vitro validation services.
Under the Agreement, GemPharmatech will pay US$114,000 in total for services performed under work orders. WORK Medical previously invested $1.0 million in Neologics on Oct 21, 2025 and, as of Oct 29, 2025, holds a 10% equity interest following Delaware shareholder registration. Neologics operates an R&D lab in San Diego and focuses on AI-integrated preclinical drug screening and target discovery.
WORK Medical (NASDAQ: WOK) agreed to invest US$1 million in Neologics Bioscience to acquire a 10% equity interest via newly issued shares, on a post-investment basis. The transaction raises Neologics's total capital reserve to US$10 million and leaves the existing shareholder with a 90% stake.
WORK Medical gains governance rights tied to its 10% holding, a right of first refusal on future equity offers, and expects Neologics to complete registration and issue an equity certificate within 20 working days. Proceeds will support operations, R&D, market expansion, and hiring.
WORK Medical Technology Group (Nasdaq: WOK) will effect a 1-for-100 reverse stock split effective October 21, 2025, with Class A shares trading on a post-split basis from market open that day under the existing ticker WOK and new CUSIP G9767H117.
The split was approved by shareholders and the board to regain compliance with Nasdaq Rule 5550(a)(2). Fractional shares will be rounded up to the next whole share. Outstanding Class A shares will fall from approximately 96.00 million to 960,000; Class B shares will fall from approximately 7.59 million to 76,000.
WORK Medical Technology Group (NASDAQ: WOK) received a Nasdaq determination letter dated October 9, 2025 notifying the company of a delisting due to its Class A ordinary shares having a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025.
Unless appealed, trading will be suspended at the open of business on October 20, 2025 and a Form 25-NSE will be filed to remove the company’s securities from Nasdaq. The company may request a hearing by October 16, 2025; a hearing request will stay the suspension. The company plans to appeal by October 16 and said it will consider options to regain compliance, including a possible reverse share split.
WORK Medical (Nasdaq: WOK) received a Nasdaq notification dated October 7, 2025 granting an additional 180-calendar-day compliance period to regain the minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company’s initial 180-day cure period expired October 6, 2025; the new deadline is April 6, 2026. To regain compliance, WOK must achieve a closing bid of $1.00 per share for at least 10 consecutive business days (Nasdaq may require up to 20 days depending on factors).
The company said it intends to cure the deficiency, including potentially implementing a reverse stock split. Trading of Class A ordinary shares on Nasdaq under WOK continues with no immediate delisting action.
WORK Medical Technology Group (NASDAQ:WOK) has announced a registered direct offering of 38,999,334 Class A ordinary shares at $0.075 per share, aiming to raise approximately $2.9 million in gross proceeds. The offering includes pre-funded warrants with an exercise price of $0.0005 per share.
The transaction, expected to close around September 26, 2025, is being conducted under a shelf registration statement on Form F-3. Univest Securities, LLC is serving as the sole placement agent for this offering.
WORK Medical Technology Group (NASDAQ:WOK) has announced a strategic partnership with the Hong Kong Web3.0 Standardization Association Limited to innovate in blockchain and Real-world Asset (RWA) solutions. The collaboration focuses on three key areas: asset tokenization, joint investment vehicles, and RWA technology development.
As part of the agreement, WORK Medical has been appointed as a Vice President Unit of the Association. The partnership aims to leverage WORK Medical's status as a Nasdaq-listed medical device manufacturer and the Association's Web3.0 expertise to develop compliant blockchain solutions for asset tokenization and cross-chain transactions.
FAQ
What is the current stock price of WORK Medical Technology Group (WOK)?
What is the market cap of WORK Medical Technology Group (WOK)?
